Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Bicycle Therapeutics plcNASDAQ: BCYC
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.13M fell 31.2% year over year, ahead of the -107.2% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +20.3% a year.
Context
- Depreciation & amortization amounted to 8.8% of revenue in FY2025, down 11.5 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -31.2% holds above the trailing-twelve-month pace of -107.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 6.42M USD
- Year-over-year change
- -10.5%
- 4-year CAGR
- +46.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.42M | -10.5% |
| FY2024 | 2024-12-31 | 7.17M | +9.6% |
| FY2023 | 2023-12-31 | 6.55M | +77.4% |
| FY2022 | 2022-12-31 | 3.69M | +161.8% |
| FY2021 | 2021-12-31 | 1.41M | — |
Depreciation & Amortization vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 depreciation & amortization of $511.27K is the 8th largest of the 10 companies compared; the peer median is $856K.
- Its year-over-year change of -107.2% is the 7th highest of 9, against a peer median of -22.0%.
- Depreciation & amortization amounts to 0.8% of revenue for BCYC, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.93M | +15.5% | +25.3% | 9.0% | |
| LTM Mar 2026 | $1.84M | -31.3% | -31.1% | 2.3% | |
| LTM Mar 2026 | $1.33M | -12.7% | -16.8% | — | |
| LTM Mar 2026 | $1.32M | -227.7% | +0.4% | 13.4% | |
| LTM Dec 2025 | $1.19M | — | — | 1.0% | |
| LTM Mar 2026 | $856K | +258.2% | +6.4% | 1.5% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
| LTM Mar 2026 | $511.27K | -107.2% | +20.3% | 0.8% | |
| LTM Mar 2026 | $468K | -128.3% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding BCYC) | $856K | -22.0% | +0.4% | 1.9% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.17M | 6.42M |
| Deferred Income Tax | (1.67M) | (4.98M) | 3.31M | (5.23M) | (850K) |
| Stock-Based Compensation | 12.08M | 26.78M | 32.48M | 38.08M | 39.46M |
| Change in Working Capital | 38.07M | 672K | 76.66M | (33.46M) | (75.75M) |
| Accounts Receivables | 4.54M | (11.35M) | (1.2M) | (11.95M) | 2.89M |
| Inventory | (4.79M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 2.56M | 8M | 3.1M | (6.87M) |
| Other Working Capital | 37.12M | 9.46M | 69.86M | (24.61M) | (71.77M) |
| Other Non-Cash Items | 2.14M | 442K | 1.04M | (2.26M) | 0 |
| Operating Cash Flow | (14.79M) | (86.11M) | (60.63M) | (164.72M) | (249.68M) |
| Capital Expenditures | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 5.49K |
| Investing Cash Flow | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.35M) |
| Debt Repayment | 15M | 0 | 0 | (31.91M) | 0 |
| Common Stock Issued | 298.54M | 5.7M | 249.35M | 544.13M | 37.09K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.18M | 989K | 682K | 7.53M | (168.09K) |
| Financing Cash Flow | 320.73M | 6.69M | 250.03M | 519.75M | (131K) |
| Effect of Forex Changes | (1.21M) | (1.12M) | 1.35M | (694K) | 804K |
| Net Change in Cash | 302.69M | (99.53M) | 187.82M | 353.1M | (251.35M) |
| Free Cash Flow | (16.82M) | (105.1M) | (63.56M) | (165.96M) | (252.61M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.